[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"fda-warning-letters-search:[\"Raye's Inc.\",\"\",\"\",\"\",\"\",1]":3,"fda-latest-sync-dates":58},{"warningLetters":4,"total":57},[5,31],{"id":6,"raw":7,"subject":12,"body_html":14,"body_text":15,"firm_name":16,"letter_id":17,"created_at":18,"fei_number":19,"letter_url":20,"updated_at":21,"action_type":22,"case_status":23,"posted_date":24,"marcs_cms_no":25,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":27,"body_fetched_at":28,"delivery_method":29,"recipient_title":19,"reference_number":19,"action_taken_date":30,"medical_device_id":19,"response_letter_date":19},197,[8,9,10,11,12,13,13,13],"\u003Ctime datetime=\"2026-05-05T04:00:00Z\">05\u002F05\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-04-24T04:00:00Z\">04\u002F24\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Frays-vitamins-726694-04242026\">Ray’s Vitamins\u003C\u002Fa>","Center for Drug Evaluation and Research (CDER)","Unapproved New Drug\u002FMisbranded","","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Rene Gonzalez\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Owner \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Ray’s Vitamins\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>6528 Greenleaf Avenue, Ste. 204\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Whittier\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>90601\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:Gonzalezr33@yahoo.com\"> Gonzalezr33@yahoo.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>April 24, 2026\u003C\u002Fp>\u003Cp>\u003Cstrong>RE: 726694\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>To Rene Gonzalez:\u003C\u002Fp>\u003Cp>This letter is to advise you that the U.S. Food and Drug Administration (FDA) reviewed your website at https:\u002F\u002Fraysvitamins.com\u002F in April 2026. The FDA has observed that your website offers “Yeicob Ácido Hialurónico” for sale in the United States.1 In addition, FDA obtained a sample of “Yeicob Ácido Hialurónico” through your website, https:\u002F\u002Fraysvitamins.com. Based on our review, this product is an unapproved new drug under section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 355(a). As explained further below, introducing or delivering this product for introduction into interstate commerce violates sections 301(d) and 505(a) of the FD&amp;C Act, 21 U.S.C. 331(d) and 355(a). Furthermore, your “Yeicob Ácido Hialurónico” product is a misbranded drug under section 502 of the FD&amp;C Act, 21 U.S.C. 352, and introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a).\u003C\u002Fp>\u003Cp>FDA confirmed through laboratory analysis that a sample of your “Yeicob Ácido Hialurónico” product contains the undeclared active pharmaceutical ingredients diclofenac and dexamethasone. Diclofenac is a non-steroidal anti-inflammatory drug (NSAID). NSAIDs may cause increased risk of cardiovascular events, such as heart attack and stroke, as well as serious gastrointestinal damage, including bleeding, ulceration, and fatal perforation of the stomach and intestines. Diclofenac may also interact with other medications and significantly increase the risk of adverse events, particularly when consumers use multiple NSAID-containing products.\u003C\u002Fp>\u003Cp>Dexamethasone is a corticosteroid commonly used to treat inflammatory conditions. Corticosteroid use can impair a person’s ability to fight infections and can cause high blood sugar levels, muscle injuries and psychiatric problems. When corticosteroids are taken for a prolonged period, or at high doses, they can suppress the adrenal gland. Abrupt discontinuation can cause withdrawal symptoms. In addition, the undeclared dexamethasone in “Yeicob Ácido Hialurónico” may cause serious side effects when combined with other medications.\u003C\u002Fp>\u003Cp>Your “Yeicob Ácido Hialurónico” product is marketed as a dietary supplement, according to information found on the labels and\u002For labeling of the product. However, under section 201(ff)(3)(B)(i) of the FD&amp;C Act, 21 U.S.C. 321(ff)(3)(B)(i), a dietary supplement may not include an article that is approved as a new drug under section 505 of the FD&amp;C Act unless that article was marketed as a dietary supplement or food before its approval as a drug. FDA approved diclofenac under the trade name Voltaren as a new drug on July 28, 1988, and approved dexamethasone under the trade name Hexadrol, as a new drug on December 21, 1960. Given that diclofenac and dexamethasone were not marketed as dietary supplements or as a food before Voltaren and Hexadrol were approved, “Yeicob Ácido Hialurónico,” which contains diclofenac and dexamethasone, is excluded from the definition of a dietary supplement under section 201(ff)(3)(B)(i) of the FD&amp;C Act, 21 U.S.C. 321(ff)(3)(B)(i).\u003C\u002Fp>\u003Cp>Moreover, we note regardless of whether your “Yeicob Ácido Hialurónico” product is excluded from the definition of a dietary supplement, it is a drug under section 201(g)(1)(B) of the FD&amp;C Act, 21 U.S.C. 321(g)(1)(B), because it is intended for, among other things, use as an arthritis treatment.\u003C\u002Fp>\u003Cp>\u003Cstrong>Unapproved New Drug\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your “Yeicob Ácido Hialurónico” product is a drug under section 201(g)(1) of the FD&amp;C Act, 21 U.S.C. 321(g)(1), because it is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For intended to affect the structure or any function of the body.\u003C\u002Fp>\u003Cp>Examples from your product labeling, including on your website that provide evidence of the intended use (as defined in 21 CFR 201.128) of this product as a drug include, but may not be limited to, the following:\u003C\u002Fp>\u003Cp>On the webpage https:\u002F\u002Fraysvitamins.com\u002Fproduct\u002Fyeicob-acido-hialuronico\u002F:\u003C\u002Fp>\u003Cul>\u003Cli>“How This Supplement Can Help You: Supports ligament and tendon function, lubricating and cushioning joint areas. Provides nutrients for joint health, including the cartilage [sic] and menisci. Helps adjust moisture absorption in the skin, preventing dehydration. Often used for joint or muscle pain related to arthritis.”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Your “Yeicob Ácido Hialurónico” product is a “new drug” under section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p), because it is not generally recognized as safe and effective (GRASE) for use under the above-described conditions prescribed, recommended, or suggested in its labeling. With certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&amp;C Act, 21 U.S.C. 355(a). No approved applications pursuant to section 505 of the FD&amp;C Act, 21 U.S.C. 355, are in effect for this product. Accordingly, this product is an unapproved new drug. The introduction or delivery for introduction into interstate commerce of this unapproved new drug product violates sections 301(d) and 505(a) of the FD&amp;C Act, 21 U.S.C. 331(d) and 355(a).\u003C\u002Fp>\u003Cp>\u003Cstrong>Misbranded Drug\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your “Yeicob Ácido Hialurónico” product is misbranded under section 502(a) of the FD&amp;C Act, 21 U.S.C. 352(a). Under section 502(a) of the FD&amp;C Act, 21 U.S.C. 352(a), a drug is misbranded if its labeling is false or misleading in any particular. Section 201(n) of the FD&amp;C Act, 21 U.S.C. 321(n), provides that, in determining whether an article’s labeling or advertising “is misleading there shall be taken into account . . . not only representations made or suggested . . . but also the extent to which the labeling or advertising fails to reveal facts material in light of such representations.” The labeling for your “Yeicob Ácido Hialurónico” product does not declare that the product contains diclofenac and dexamethasone. As previously mentioned, these undeclared ingredients in your “Yeicob Ácido Hialurónico” product may pose serious health risks because consumers with underlying medical issues may take the product without knowing that it can cause serious harm or interact in dangerous ways with other drugs they may be taking. The failure to disclose these ingredients in the product labeling renders your “Yeicob Ácido Hialurónico” product misbranded under section 502(a) of the FD&amp;C Act, 21 U.S.C. 352(a). The introduction or delivery for introduction into interstate commerce of this misbranded drug is a prohibited act under section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a).\u003C\u002Fp>\u003Cp>We also observed that your website https:\u002F\u002Fraysvitamins.com\u002F offers “RM Joe”2 and “RMSOL GRACIAN”3 for sale to consumers in the United States. Previous FDA lab analyses of products similarly named to those sold on your website revealed these products contained undeclared drug ingredients. While the Agency has not sampled and tested these product variations from your inventory to date, this letter expresses our serious concern about the safety of these products. We emphasize that it is your legal responsibility under federal law to ensure that products you sell do not contain any undeclared or potentially harmful ingredients, and that they are marketed in compliance with applicable laws.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The violations cited in this letter are not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may lead to regulatory or legal action including, without limitation, seizure and injunction.\u003C\u002Fp>\u003Cp>Please notify FDA in writing, within fifteen working days of receipt of this letter, of the specific steps you have taken to correct any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. If you cannot complete corrective action within fifteen working days, state the reason for the delay and the time within which you will complete the correction.\u003C\u002Fp>\u003Cp>Your response should be sent to U.S. Food and Drug Administration, CDER\u002FOC\u002FOffice of Unapproved Drugs and Labeling Compliance by email to FDAAdvisory@fda.hhs.gov. Please include your firm name and the unique identifier “726694” in the subject line of the email.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003Cbr>Tina Smith, M.S.\u003Cbr>Captain, U.S. Public Health Service\u003Cbr>Director\u003Cbr>Office of Unapproved Drugs and Labeling Compliance\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003Cbr>Food and Drug Administration\u003C\u002Fp>\u003Cp>_________________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> FDA issued a warning to consumers not to use your “Yeicob Ácido Hialurónico” product (see: https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fmedication-health-fraud-notifications\u002Fyeicob-acido-hialuronico-may-be-harmful-due-hidden-drug-ingredients)\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fmedication-health-fraud-notifications\u002Frm-joe-may-be-harmful-due-hidden-drug-ingredients\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fmedication-health-fraud\u002Frmsol-gracian-contains-hidden-drug-ingredient\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nRene Gonzalez\n\nRecipient Title\n\nOwner\n\nRay’s Vitamins\n\n6528 Greenleaf Avenue, Ste. 204\n\nWhittier, CA 90601\n\nUnited States\n\nGonzalezr33@yahoo.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWARNING LETTER\nApril 24, 2026\nRE: 726694\nTo Rene Gonzalez:\nThis letter is to advise you that the U.S. Food and Drug Administration (FDA) reviewed your website at https:\u002F\u002Fraysvitamins.com\u002F in April 2026. The FDA has observed that your website offers “Yeicob Ácido Hialurónico” for sale in the United States.1 In addition, FDA obtained a sample of “Yeicob Ácido Hialurónico” through your website, https:\u002F\u002Fraysvitamins.com. Based on our review, this product is an unapproved new drug under section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 355(a). As explained further below, introducing or delivering this product for introduction into interstate commerce violates sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a). Furthermore, your “Yeicob Ácido Hialurónico” product is a misbranded drug under section 502 of the FD&C Act, 21 U.S.C. 352, and introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FD&C Act, 21 U.S.C. 331(a).\nFDA confirmed through laboratory analysis that a sample of your “Yeicob Ácido Hialurónico” product contains the undeclared active pharmaceutical ingredients diclofenac and dexamethasone. Diclofenac is a non-steroidal anti-inflammatory drug (NSAID). NSAIDs may cause increased risk of cardiovascular events, such as heart attack and stroke, as well as serious gastrointestinal damage, including bleeding, ulceration, and fatal perforation of the stomach and intestines. Diclofenac may also interact with other medications and significantly increase the risk of adverse events, particularly when consumers use multiple NSAID-containing products.\nDexamethasone is a corticosteroid commonly used to treat inflammatory conditions. Corticosteroid use can impair a person’s ability to fight infections and can cause high blood sugar levels, muscle injuries and psychiatric problems. When corticosteroids are taken for a prolonged period, or at high doses, they can suppress the adrenal gland. Abrupt discontinuation can cause withdrawal symptoms. In addition, the undeclared dexamethasone in “Yeicob Ácido Hialurónico” may cause serious side effects when combined with other medications.\nYour “Yeicob Ácido Hialurónico” product is marketed as a dietary supplement, according to information found on the labels and\u002For labeling of the product. However, under section 201(ff)(3)(B)(i) of the FD&C Act, 21 U.S.C. 321(ff)(3)(B)(i), a dietary supplement may not include an article that is approved as a new drug under section 505 of the FD&C Act unless that article was marketed as a dietary supplement or food before its approval as a drug. FDA approved diclofenac under the trade name Voltaren as a new drug on July 28, 1988, and approved dexamethasone under the trade name Hexadrol, as a new drug on December 21, 1960. Given that diclofenac and dexamethasone were not marketed as dietary supplements or as a food before Voltaren and Hexadrol were approved, “Yeicob Ácido Hialurónico,” which contains diclofenac and dexamethasone, is excluded from the definition of a dietary supplement under section 201(ff)(3)(B)(i) of the FD&C Act, 21 U.S.C. 321(ff)(3)(B)(i).\nMoreover, we note regardless of whether your “Yeicob Ácido Hialurónico” product is excluded from the definition of a dietary supplement, it is a drug under section 201(g)(1)(B) of the FD&C Act, 21 U.S.C. 321(g)(1)(B), because it is intended for, among other things, use as an arthritis treatment.\nUnapproved New Drug\nYour “Yeicob Ácido Hialurónico” product is a drug under section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1), because it is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For intended to affect the structure or any function of the body.\nExamples from your product labeling, including on your website that provide evidence of the intended use (as defined in 21 CFR 201.128) of this product as a drug include, but may not be limited to, the following:\nOn the webpage https:\u002F\u002Fraysvitamins.com\u002Fproduct\u002Fyeicob-acido-hialuronico\u002F:\n“How This Supplement Can Help You: Supports ligament and tendon function, lubricating and cushioning joint areas. Provides nutrients for joint health, including the cartilage [sic] and menisci. Helps adjust moisture absorption in the skin, preventing dehydration. Often used for joint or muscle pain related to arthritis.”\nYour “Yeicob Ácido Hialurónico” product is a “new drug” under section 201(p) of the FD&C Act, 21 U.S.C. 321(p), because it is not generally recognized as safe and effective (GRASE) for use under the above-described conditions prescribed, recommended, or suggested in its labeling. With certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&C Act, 21 U.S.C. 355(a). No approved applications pursuant to section 505 of the FD&C Act, 21 U.S.C. 355, are in effect for this product. Accordingly, this product is an unapproved new drug. The introduction or delivery for introduction into interstate commerce of this unapproved new drug product violates sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a).\nMisbranded Drug\nYour “Yeicob Ácido Hialurónico” product is misbranded under section 502(a) of the FD&C Act, 21 U.S.C. 352(a). Under section 502(a) of the FD&C Act, 21 U.S.C. 352(a), a drug is misbranded if its labeling is false or misleading in any particular. Section 201(n) of the FD&C Act, 21 U.S.C. 321(n), provides that, in determining whether an article’s labeling or advertising “is misleading there shall be taken into account . . . not only representations made or suggested . . . but also the extent to which the labeling or advertising fails to reveal facts material in light of such representations.” The labeling for your “Yeicob Ácido Hialurónico” product does not declare that the product contains diclofenac and dexamethasone. As previously mentioned, these undeclared ingredients in your “Yeicob Ácido Hialurónico” product may pose serious health risks because consumers with underlying medical issues may take the product without knowing that it can cause serious harm or interact in dangerous ways with other drugs they may be taking. The failure to disclose these ingredients in the product labeling renders your “Yeicob Ácido Hialurónico” product misbranded under section 502(a) of the FD&C Act, 21 U.S.C. 352(a). The introduction or delivery for introduction into interstate commerce of this misbranded drug is a prohibited act under section 301(a) of the FD&C Act, 21 U.S.C. 331(a).\nWe also observed that your website https:\u002F\u002Fraysvitamins.com\u002F offers “RM Joe”2 and “RMSOL GRACIAN”3 for sale to consumers in the United States. Previous FDA lab analyses of products similarly named to those sold on your website revealed these products contained undeclared drug ingredients. While the Agency has not sampled and tested these product variations from your inventory to date, this letter expresses our serious concern about the safety of these products. We emphasize that it is your legal responsibility under federal law to ensure that products you sell do not contain any undeclared or potentially harmful ingredients, and that they are marketed in compliance with applicable laws.\nConclusion\nThe violations cited in this letter are not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may lead to regulatory or legal action including, without limitation, seizure and injunction.\nPlease notify FDA in writing, within fifteen working days of receipt of this letter, of the specific steps you have taken to correct any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. If you cannot complete corrective action within fifteen working days, state the reason for the delay and the time within which you will complete the correction.\nYour response should be sent to U.S. Food and Drug Administration, CDER\u002FOC\u002FOffice of Unapproved Drugs and Labeling Compliance by email to FDAAdvisory@fda.hhs.gov. Please include your firm name and the unique identifier “726694” in the subject line of the email.\nSincerely,\n\u002FS\u002F\nTina Smith, M.S.\nCaptain, U.S. Public Health Service\nDirector\nOffice of Unapproved Drugs and Labeling Compliance\nOffice of Compliance\nCenter for Drug Evaluation and Research\nFood and Drug Administration\n_________________________\n1 FDA issued a warning to consumers not to use your “Yeicob Ácido Hialurónico” product (see: https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fmedication-health-fraud-notifications\u002Fyeicob-acido-hialuronico-may-be-harmful-due-hidden-drug-ingredients)\n2 https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fmedication-health-fraud-notifications\u002Frm-joe-may-be-harmful-due-hidden-drug-ingredients\n3 https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fmedication-health-fraud\u002Frmsol-gracian-contains-hidden-drug-ingredient","Ray’s Vitamins","rays-vitamins-726694-04242026","2026-08-18T06:42:28.498414+00:00",null,"https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Frays-vitamins-726694-04242026","2026-10-26T08:09:47.412086+00:00","Warning Letter","Issued","2026-05-05","726694","Drugs","Rene Gonzalez","2026-08-19T04:44:47.704+00:00","Via Email","2026-04-24",{"id":32,"raw":33,"subject":38,"body_html":40,"body_text":41,"firm_name":42,"letter_id":43,"created_at":44,"fei_number":19,"letter_url":45,"updated_at":46,"action_type":22,"case_status":47,"posted_date":48,"marcs_cms_no":49,"product_type":50,"closeout_date":51,"issuing_office":52,"recipient_name":53,"body_fetched_at":54,"delivery_method":55,"recipient_title":19,"reference_number":19,"action_taken_date":56,"medical_device_id":19,"response_letter_date":19},2324,[34,35,36,37,38,13,39,13],"\u003Ctime datetime=\"2022-11-22T14:20:00Z\">11\u002F22\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-10-18T04:00:00Z\">10\u002F18\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Frosebuds-ranch-and-garden-llc-628567-10182022\">Rosebud&#039;s Ranch and Garden, LLC\u003C\u002Fa>"," Division of Human and Animal Food Operations East V ","New Drug\u002FMisbranded","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Frosebuds-ranch-and-garden-llc-628567-03312023\">\u003Ctime datetime=\"2023-04-07T04:00:00Z\">04\u002F07\u002F2023\u003C\u002Ftime>\n\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>United Parcel Service\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs\u003Cbr>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Amber R. Stephenson\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Owner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Rosebud's Ranch and Garden, LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>122 W High St.\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Piqua\u003C\u002Fspan>, \u003Cspan>OH\u003C\u002Fspan> \u003Cspan>45356\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd> Division of Human and Animal Food Operations East V \u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter # 628567\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>10\u002F18\u002F2022\u003C\u002Fp>\n\n\u003Cp>Dear Ms. Stephenson:\u003C\u002Fp>\n\n\u003Cp>This is to advise you that the Food and Drug Administration (FDA) reviewed your website at the Internet address www.rosebudsrealfood.com and your social media website at www.facebook.com\u002FRosebudsRealFood in June and August 2022, from which sites you take orders for Domestic Divas – Colds and Flu (Tea), Domestic Divas - No Pain No Gain Tea, Green Feather Homestead Mad As A Hatter Chai Tea, Rosebud’s Natural Seasonings Elderberry Syrup Kit, Rosebud’s Elderberry Lemonade, Rosebud’s Herbs &amp; Spices Sencha Tea, Rosebud’s Natural Seasonings Jane’s Italian, Rosebud’s Fruit Butters Peach Blueberry, Rosebud’s Real Food Raw! Habanero Sriracha, and Rosebud’s Real Food Supertonic! Sriracha. The claims on your websites establish the products are drugs under section 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. 321(g)(1)(B)] because they are intended for use in the cure, mitigation, treatment, or prevention of disease. As explained further below, introducing or delivering these products for introduction into interstate commerce for such uses violates the Act. You can find the FD&amp;C Act and FDA regulations through links on FDA’s home page at \u003Ca>www.fda.gov.\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Cp>Examples of some of the claims that provide evidence that your products are intended for use as drugs include:\u003C\u002Fp>\n\n\u003Cp>Domestic Divas - Colds and Flu (Tea)\u003Cbr>\n&nbsp; &nbsp; “Eases the discomfort of a cold or flu”\u003C\u002Fp>\n\n\u003Cp>Domestic Divas - No Pain No Gain Tea\u003Cbr>\n&nbsp; &nbsp; “Eases Muscular Pain”\u003C\u002Fp>\n\n\u003Cp>Green Feather Homestead Mad As A Hatter Chai Tea\u003Cbr>\n&nbsp; &nbsp; “balancing to blood sugar”\u003Cbr>\n\u003Cbr>\nRosebud’s Natural Seasonings Elderberry Syrup Kit: From the product label, as shown on an image on your website at www.rosebudsrealfood.com\u002Fproducts\u002Felderberry-syrupkit?_pos=1&amp;_sid=4f1ea37c2&amp;_ss=r:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“Standard dose is ½ tsp - 1 tsp for kids and ½ - 1 tablespoon for adults. If the flu does strike, take the normal dose every 2-3 hours instead of once a day until symptoms disappear”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Rosebud’s Elderberry Lemonade, Rosebud’s Natural Seasonings Elderberry Syrup Kit (Elderberry ingredient): www.facebook.com\u002FRosebudsRealFood\u003C\u002Fp>\n\n\u003Cp>Facebook Post Date February 3, 2022\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>&nbsp;“‘Health benefits of the elder plant [elderberry] include naturally improving sinus issues, nerve pain, inflammation, chronic fatigue, allergies, constipation and even cancer. When used within the first 48 hours of onset of symptoms, the extract may even help relieve and shorten the duration of cold and flu symptoms as well.”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Facebook Post Date September 3, 2021\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>&nbsp;“Cancer Preventer”\u003C\u002Fli>\n\t\u003Cli>&nbsp;“Blood Sugar Balancer”\u003C\u002Fli>\n\t\u003Cli>&nbsp;“Cold &amp; Flu Fighter”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Rosebud’s Herbs &amp; Spices Sencha Tea: www.facebook.com\u002FRosebudsRealFood\u003C\u002Fp>\n\n\u003Cp>Facebook Post Date January 4, 2022\u003C\u002Fp>\n\n\u003Cp>“Potential benefits of sencha green tea include:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>&nbsp;anti-cancer properties\u003C\u002Fli>\n\t\u003Cli>&nbsp;prevention of neurodegenerative diseases\u003C\u002Fli>\n\t\u003Cli>&nbsp;anti-inflammatory properties\u003C\u002Fli>\n\t\u003Cli>&nbsp;lowering bad cholesterol\u003C\u002Fli>\n\t\u003Cli>&nbsp;anti-bacterial properties\u003C\u002Fli>\n\t\u003Cli>&nbsp;prevention of some bacterial and virus infections\u003C\u002Fli>\n\t\u003Cli>&nbsp;preventing tooth decay”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Real Food Raw! Habanero Sriracha, Natural Seasonings Jane’s Italian, and Real Food Supertonic! Sriracha (all of which contain garlic as an ingredient): www.facebook.com\u002FRosebudsRealFood\u003C\u002Fp>\n\n\u003Cp>Facebook Post Date January 22, 2022\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>&nbsp;“Garlic is antiviral, antibacterial, antifungal (including anti-mold), anti-parasitic, and rich in the phytochemical allicin, a sulfur compound that prevents disease.”\u003C\u002Fli>\n\t\u003Cli>&nbsp;“Garlic kills off pathogens such as viruses and unproductive bacteria, which are behind so many mystery and chronic illnesses and symptoms.”\u003C\u002Fli>\n\t\u003Cli>&nbsp;“Garlic helps fight colds, flus, strep throat, pneumonia-causing bacteria, and viral-related cancers.”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Facebook Post Date January 9, 2022\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>&nbsp;“Eat some garlic and lower that blood pressure!”\u003C\u002Fli>\n\t\u003Cli>&nbsp;“Garlic has anti-inflammatory benefits and helps blood flow more easily through the body. Several studies found that blood pressure was lowered by 10%!!!!”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Rosebud’s Elderberry Lemonade and Rosebud’s Fruit Butters Peach Blueberry (which contain lemon): www.facebook.com\u002FRosebudsRealFood\u003C\u002Fp>\n\n\u003Cp>Facebook Post Date February 19, 2022\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>&nbsp;“[P]hytochemicals called limonoids in lemons and limes actually bond the vitamin C and calcium together, so that wherever one goes in the body, the other rides along. This enhances the bioavailability of each, and also creates alkalinity in the body to help prevent the growth of almost every type of cancer”\u003C\u002Fli>\n\t\u003Cli>&nbsp;“The antioxidant flavonoids in lemons and limes are another ally in fighting disease. And when you’re dealing with a cold, flu, bronchitis, or pneumonia, lemon is one of the most effective mucus expellers you can find.”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Your products are not generally recognized as safe and effective for the above referenced uses and, therefore, the products are “new drugs” under section 201(p) of the Act [21 U.S.C. 321(p)]. With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301(d) and 505(a) of the Act [21 U.S.C. 331(d), 355(a)]. FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective.\u003C\u002Fp>\n\n\u003Cp>A drug is misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 CFR 201.5). Prescription drugs, as defined in section 503(b)(1)(A) of the Act [21 U.S.C. 353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.\u003C\u002Fp>\n\n\u003Cp>Your products Rosebud’s Natural Seasonings Elderberry Syrup Kit, Rosebud’s Elderberry Lemonade, Rosebud’s Real Food Raw! Habanero Sriracha, Rosebud’s Natural Seasonings Jane’s Italian, Rosebud’s Fruit Butters Peach Blueberry, Rosebud’s Herbs &amp; Spices Sencha Tea and Rosebud’s Real Food Supertonic! Sriracha are intended for treatment of one or more diseases that are not amenable to self-diagnosis or treatment without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use your product safely for its intended purpose. Accordingly, Rosebud’s Natural Seasonings Elderberry Syrup Kit, Rosebud’s Elderberry Lemonade, Rosebud’s Real Food Raw! Habanero Sriracha, Rosebud’s Natural Seasonings Jane’s Italian, Rosebud’s Fruit Butters Peach Blueberry, Rosebud’s Herbs &amp; Spices Sencha Tea, and Rosebud’s Real Food Supertonic! Sriracha fail to bear adequate directions for their intended use and, therefore, the products are misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)]. The introduction or delivery for introduction into interstate commerce of these misbranded drugs violates section 301(a) of the Act [21 U.S.C. 331(a)].\u003C\u002Fp>\n\n\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>Please notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Your reply should be addressed to the U.S. Food and Drug Administration; Attn: Christopher N. Dedeaux, Compliance Officer, via email at ORAHAFEAST5FirmResponses@fda.hhs.gov or at 404 BNA Drive, Suite 500, Nashville, TN 37217. You may reach Mr. Dedeaux at 504-846-6122 or via email at Christopher.Dedeaux@fda.hhs.gov if you have any questions about this matter.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Steven B. Barber\u003Cbr>\nDirector, Division V\u003Cbr>\nOffice of Human and Animal Foods Operations-East\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nUnited Parcel Service\n\nProduct:\n\nDrugs\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nAmber R. Stephenson\n\nRecipient Title\n\nOwner\n\nRosebud's Ranch and Garden, LLC\n\n122 W High St.\n\nPiqua, OH 45356\n\nUnited States\n\nIssuing Office:\n\nDivision of Human and Animal Food Operations East V\n\nUnited States\n\nWarning Letter # 628567\n\n10\u002F18\u002F2022\n\nDear Ms. Stephenson:\n\nThis is to advise you that the Food and Drug Administration (FDA) reviewed your website at the Internet address www.rosebudsrealfood.com and your social media website at www.facebook.com\u002FRosebudsRealFood in June and August 2022, from which sites you take orders for Domestic Divas – Colds and Flu (Tea), Domestic Divas - No Pain No Gain Tea, Green Feather Homestead Mad As A Hatter Chai Tea, Rosebud’s Natural Seasonings Elderberry Syrup Kit, Rosebud’s Elderberry Lemonade, Rosebud’s Herbs & Spices Sencha Tea, Rosebud’s Natural Seasonings Jane’s Italian, Rosebud’s Fruit Butters Peach Blueberry, Rosebud’s Real Food Raw! Habanero Sriracha, and Rosebud’s Real Food Supertonic! Sriracha. The claims on your websites establish the products are drugs under section 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. 321(g)(1)(B)] because they are intended for use in the cure, mitigation, treatment, or prevention of disease. As explained further below, introducing or delivering these products for introduction into interstate commerce for such uses violates the Act. You can find the FD&C Act and FDA regulations through links on FDA’s home page at www.fda.gov.\n\nExamples of some of the claims that provide evidence that your products are intended for use as drugs include:\n\nDomestic Divas - Colds and Flu (Tea)\n\n“Eases the discomfort of a cold or flu”\n\nDomestic Divas - No Pain No Gain Tea\n\n“Eases Muscular Pain”\n\nGreen Feather Homestead Mad As A Hatter Chai Tea\n\n“balancing to blood sugar”\n\nRosebud’s Natural Seasonings Elderberry Syrup Kit: From the product label, as shown on an image on your website at www.rosebudsrealfood.com\u002Fproducts\u002Felderberry-syrupkit?_pos=1&_sid=4f1ea37c2&_ss=r:\n\n“Standard dose is ½ tsp - 1 tsp for kids and ½ - 1 tablespoon for adults. If the flu does strike, take the normal dose every 2-3 hours instead of once a day until symptoms disappear”\n\nRosebud’s Elderberry Lemonade, Rosebud’s Natural Seasonings Elderberry Syrup Kit (Elderberry ingredient): www.facebook.com\u002FRosebudsRealFood\n\nFacebook Post Date February 3, 2022\n\n“‘Health benefits of the elder plant [elderberry] include naturally improving sinus issues, nerve pain, inflammation, chronic fatigue, allergies, constipation and even cancer. When used within the first 48 hours of onset of symptoms, the extract may even help relieve and shorten the duration of cold and flu symptoms as well.”\n\nFacebook Post Date September 3, 2021\n\n“Cancer Preventer”\n\n“Blood Sugar Balancer”\n\n“Cold & Flu Fighter”\n\nRosebud’s Herbs & Spices Sencha Tea: www.facebook.com\u002FRosebudsRealFood\n\nFacebook Post Date January 4, 2022\n\n“Potential benefits of sencha green tea include:\n\nanti-cancer properties\n\nprevention of neurodegenerative diseases\n\nanti-inflammatory properties\n\nlowering bad cholesterol\n\nanti-bacterial properties\n\nprevention of some bacterial and virus infections\n\npreventing tooth decay”\n\nReal Food Raw! Habanero Sriracha, Natural Seasonings Jane’s Italian, and Real Food Supertonic! Sriracha (all of which contain garlic as an ingredient): www.facebook.com\u002FRosebudsRealFood\n\nFacebook Post Date January 22, 2022\n\n“Garlic is antiviral, antibacterial, antifungal (including anti-mold), anti-parasitic, and rich in the phytochemical allicin, a sulfur compound that prevents disease.”\n\n“Garlic kills off pathogens such as viruses and unproductive bacteria, which are behind so many mystery and chronic illnesses and symptoms.”\n\n“Garlic helps fight colds, flus, strep throat, pneumonia-causing bacteria, and viral-related cancers.”\n\nFacebook Post Date January 9, 2022\n\n“Eat some garlic and lower that blood pressure!”\n\n“Garlic has anti-inflammatory benefits and helps blood flow more easily through the body. Several studies found that blood pressure was lowered by 10%!!!!”\n\nRosebud’s Elderberry Lemonade and Rosebud’s Fruit Butters Peach Blueberry (which contain lemon): www.facebook.com\u002FRosebudsRealFood\n\nFacebook Post Date February 19, 2022\n\n“[P]hytochemicals called limonoids in lemons and limes actually bond the vitamin C and calcium together, so that wherever one goes in the body, the other rides along. This enhances the bioavailability of each, and also creates alkalinity in the body to help prevent the growth of almost every type of cancer”\n\n“The antioxidant flavonoids in lemons and limes are another ally in fighting disease. And when you’re dealing with a cold, flu, bronchitis, or pneumonia, lemon is one of the most effective mucus expellers you can find.”\n\nYour products are not generally recognized as safe and effective for the above referenced uses and, therefore, the products are “new drugs” under section 201(p) of the Act [21 U.S.C. 321(p)]. With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301(d) and 505(a) of the Act [21 U.S.C. 331(d), 355(a)]. FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective.\n\nA drug is misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 CFR 201.5). Prescription drugs, as defined in section 503(b)(1)(A) of the Act [21 U.S.C. 353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.\n\nYour products Rosebud’s Natural Seasonings Elderberry Syrup Kit, Rosebud’s Elderberry Lemonade, Rosebud’s Real Food Raw! Habanero Sriracha, Rosebud’s Natural Seasonings Jane’s Italian, Rosebud’s Fruit Butters Peach Blueberry, Rosebud’s Herbs & Spices Sencha Tea and Rosebud’s Real Food Supertonic! Sriracha are intended for treatment of one or more diseases that are not amenable to self-diagnosis or treatment without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use your product safely for its intended purpose. Accordingly, Rosebud’s Natural Seasonings Elderberry Syrup Kit, Rosebud’s Elderberry Lemonade, Rosebud’s Real Food Raw! Habanero Sriracha, Rosebud’s Natural Seasonings Jane’s Italian, Rosebud’s Fruit Butters Peach Blueberry, Rosebud’s Herbs & Spices Sencha Tea, and Rosebud’s Real Food Supertonic! Sriracha fail to bear adequate directions for their intended use and, therefore, the products are misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)]. The introduction or delivery for introduction into interstate commerce of these misbranded drugs violates section 301(a) of the Act [21 U.S.C. 331(a)].\n\nThis letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\n\nPlease notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\n\nYour reply should be addressed to the U.S. Food and Drug Administration; Attn: Christopher N. Dedeaux, Compliance Officer, via email at ORAHAFEAST5FirmResponses@fda.hhs.gov or at 404 BNA Drive, Suite 500, Nashville, TN 37217. You may reach Mr. Dedeaux at 504-846-6122 or via email at Christopher.Dedeaux@fda.hhs.gov if you have any questions about this matter.\n\nSincerely,\n\n\u002FS\u002F\n\nSteven B. Barber\n\nDirector, Division V\n\nOffice of Human and Animal Foods Operations-East","Rosebud's Ranch and Garden, LLC","rosebuds-ranch-and-garden-llc-628567-10182022","2026-08-18T06:42:29.145918+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Frosebuds-ranch-and-garden-llc-628567-10182022","2026-10-26T08:09:51.131225+00:00","Closed Out","2022-11-22","628567","DrugsFood & Beverages","2023-04-07","Division of Human and Animal Food Operations East V","Amber R. Stephenson","2026-08-20T01:24:47.789+00:00","United Parcel Service","2022-10-18",2,{"510k":59,"classification":60,"enforcement":61,"event":62,"event_backfill":63,"pma":64,"warning_letter":65},"2026-11-16T02:00:55.89+00:00","2026-11-16T02:00:41.999+00:00","2026-11-16T02:00:49.415+00:00","2026-11-18T04:00:44.748+00:00","2026-09-07T05:17:28.839+00:00","2026-11-16T02:01:03.155+00:00","2026-11-17T01:02:55.859+00:00"]